IP Library Patent Application 18943446
Patent Application
App. No. 18/943,446

ASSESSMENT OF PREECLAMPSIA USING ASSAYS FOR FREE AND DISSOCIATED PLACENTAL GROWTH FACTOR

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/943,446
Abstract

Described herein are methods, compositions, kits, and systems for detecting free and bound PlGF, and using detection of such species to distinguish between pregnant women with or without preeclampsia or related conditions.

Claims (25)

1 - 96 . (canceled)

97 . A kit for assessing a risk of preeclampsia or ruling out preeclampsia in a pregnant female subject, the kit comprising:

(a) an agent or apparatus for dissociating placental growth factor (PlGF) from a PlGF complex with another protein;

(b) at least one probe for specific binding to PlGF; and

(c) instructions for use, the instructions directing to perform the steps for determining levels of free and dissociated PlGF in a biological sample by (1) collecting a biological sample from a pregnant female subject, (2) obtaining first and second aliquots of the biological sample, (3) measuring an amount of PlGF-f in the first aliquot of the sample, (4) applying a treatment to the second aliquot of the sample, and (5) measuring an amount of PlGF-d in the second aliquot of the sample,

wherein the instructions further note that a PlGF-f:PlGF-d ratio less than a first threshold value indicates a heightened risk that the pregnant female subject will suffer from preeclampsia, and that a PlGF-f:PlGF-d ration greater than a second threshold value indicates a reduced risk that the pregnant female subject will suffer from preeclampsia, wherein the first threshold value and second threshold value are the same and are determined using a threshold analysis method disclosed in the instructions.

98 . The kit of claim 97 , wherein the kit is designed to measure the levels of no more than 10 different biomarkers, with no more than 10 biomarker-specific probes, antibodies, or antigen binding fragments or derivatives of antibodies present.

99 . The kit of claim 98 , wherein the kit further comprises at least one prove for specific binding to at least one of sFLT, Endoglin, KIM-1, and FGF21.

100 . The kit of claim 98 , wherein the kit is an enzyme-linked immunosorbent assay kit.

101 . The kit of claim 97 , wherein the at least one probe is attached to a substrate.

102 . The kit of claim 97 , wherein the kit is for a lateral flow immunoassay.

103 . The kit of claim 97 , further comprising a collection tube for collecting a biological sample from the pregnant female subject.

104 . The kit of claim 103 , wherein the collection tube is suitable for collection of serum or plasma.

105 . The kit of claim 97 , wherein the at least one prove for specific binding to PlGF comprises an antibody or antigen-binding fragment.

106 . The kit of claim 99 , wherein the at least one probe for specific binding to at least one of sFLT, Endoglin, KIM-1, and FGF21 comprises an antibody or antigen-binding fragment.

107 . The kit of claim 97 , further comprising a microwell or multiwell plate.

108 . The kit of claim 107 , wherein the microwell or multiwell plate comprises at least one well with the at least one prove for specific binding to PlGF.

109 . The kit of claim 97 , wherein the kit comprises the agent for dissociating placental growth factor from the PLGF complex with another protein.

110 . The kit of claim 109 , wherein the agent for dissociating placental growth factor from the PlGF complex with another protein is selected from a surfactant, a detergent, a chaotropic agent, a PlGF-binding protein, and an sFLT-binding protein.

111 . The kit of claim 109 , wherein the agent for dissociating placental growth factor from the PlGF complex with another protein is a surfactant.

112 . The kit of claim 109 , wherein the agent for dissociating placental growth factor from the PlGF complex with another protein is a detergent.

113 . The kit of claim 109 , wherein the agent from dissociating placental growth factor from the PlGF complex with another protein is a chaotropic agent.

114 . The kit of claim 109 , wherein the agent for dissociating placental growth factor from the PlGF complex with another protein is a pH adjustment agent.

115 . The kit of claim 97 , wherein the kit comprises the apparatus for dissociating placental growth factor from the PlGF complex with another protein.

116 . The kit of claim 115 , wherein the apparatus comprises a heating element.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 6, 2026
From: BT BIDCO, INC. (DBA BIORA THERAPEUTICS)
To: MOMM DIAGNOSTICS AG
Reel/Frame 073374/0273 →
RELEASE OF SECURITY INTEREST Recorded Dec 16, 2025
From: GLAS USA LLC
To: BT BIDCO, INC.
Reel/Frame 073229/0061 →